News
ALLO
--
0.00%
--
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7)
Benzinga · 06/08 13:17
The Bottom Is in for These 3 Stocks? Analysts Say ‘Buy’
We all want to build a profitable portfolio – but if you’re new to the markets, and starting from scratch, where do you begin? It’s tempting to buy into the big names, the companies that have been making waves and generating headlines. Tempting, but probab...
TipRanks · 06/07 15:11
Stocks That Hit 52-Week Lows On Monday
    Before 10 a.m. ET Monday, 8 stocks made new 52-week lows.
Benzinga · 06/07 14:05
Why Is Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report?
Zacks.com · 06/04 15:31
The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3)
Benzinga · 06/04 13:39
Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology
-- ASCO Posters Detail Results from ALLO-501 ALPHA and ALLO-501A ALPHA2 Trials in Non-Hodgkin Lymphoma and Safety and PK/PD Data of ALLO-647 with Flu/Cy Across the ALPHA, ALPHA2 and UNIVERSAL Studies
GlobeNewswire · 06/04 13:00
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.
Benzinga · 05/31 15:06
The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25)
Benzinga · 05/26 11:33
CAR T therapy competition heats up as Allogene plans pivotal trial
Allogene (ALLO) plans to initiate a pivotal trial of its off-the-shelf CAR T therapy ALLO-501A by the end of the year.The disclosure was made May 20 as the company reported
Seekingalpha · 05/24 14:00
Allogene Therapeutics Shares Drop 7% After Results for Lymphoma Treatment
By Chris Wack Allogene Therapeutics Inc. shares were down 7% to $26.69 after the company said it saw positive results from its Phase 1 trial in...
marketwatch.com · 05/20 17:20
How Small Biotech Allogene Is Making Waves For Gilead, Novartis
Allogene Therapeutics said its donor cell-derived cancer treatment was successful for six months, and ALLO stock popped Thursday.
Investor's Business Daily · 05/20 14:45
Cancer Biotechs Are on the Move in Advance of Big Conference
Dozens of companies released data in advance of the American Society of Clinical Oncology gathering, which begins June 4.
Barrons.com · 05/20 14:15
Merck downgraded to hold at Argus, Allogene upped at Truist, and more in today's analyst action
Merck downgraded on Organon spinoff impactArgus has downgraded Merck (MRK) from buy to hold ahead of next month's spinoff of the Organon division and the implications it might have on
Seekingalpha · 05/20 14:12
Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2021
 
Benzinga · 05/20 14:02
Thinking About Buying Stock In Entera Bio, Allogene Or Vistagen?
Entera Bio Ltd (NASDAQ: ENTX) shares are trading higher by 3.3% at $3.10 Thursday morning after the company reported first-quarter sales results that showed year-over-year improvement. 
Benzinga · 05/20 13:14
Thinking about buying stock in Virgin Galactic, Vistagen Therapeutics, PDS Biotechnology, Super League Gaming, or Allogene Therapeutics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPCE, VTGN, PDSB, SLGG, and ALLO.
PR Newswire - PRF · 05/20 12:30
Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T(TM)) therapies for cancer, today announced that management plans to participate in five upcoming virtual investor c...
GlobeNewswire · 05/20 12:30
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19)
Benzinga · 05/20 12:27
SPCE, RIOT, ONCT and HIMS among premarket gainers
Virgin Galactic Holdings SPCE +21% after test flight scheduled for May 22.VistaGen Therapeutics VTGN +15% after Baird calls stock 'significantly undervalued'.Allogene Therapeutics ALLO +13% on positive early-stage data for CAR T candidates in blood cancer....
Seekingalpha · 05/20 12:27
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Benzinga · 05/20 12:14
Webull provides a variety of real-time ALLO stock news. You can receive the latest news about Allogene Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About ALLO
Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on developing and commercializing of allogeneic T cell therapies for the treatment of cancer. It is involved in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and T cell manufacturing technologies. Its T cell product candidates are designed to target and kill cancer cells. Its product candidate includes UCART19, ALLO-501, ALLO-715 and ALLO-647. The Company’s UCART19 is an allogeneic CAR T cell therapy that targets CD19. The Company’s ALLO-501 is an allogeneic anti-CD19 CAR T cell product candidate, which is designed for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). The Company’s ALLO-715 targets B-cell maturation antigen (BCMA) for the treatment of patients with R/R multiple myeloma.